Philip Bonomi to Quinazolines
This is a "connection" page, showing publications Philip Bonomi has written about Quinazolines.
Connection Strength
2.102
-
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
Score: 0.426
-
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
Score: 0.413
-
The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007 May; 2(5):414-22.
Score: 0.301
-
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47.
Score: 0.250
-
Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer. Am J Health Syst Pharm. 2003 Dec 15; 60(24 Suppl 9):S16-21.
Score: 0.238
-
Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs. 2003 Aug; 12(8):1395-401.
Score: 0.232
-
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008 Nov 20; 26(33):5407-15.
Score: 0.083
-
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94.
Score: 0.080
-
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer. 2003 Aug; 41 Suppl 1:S43-8.
Score: 0.058
-
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007 Oct 20; 25(30):4743-50.
Score: 0.019